Positive clinical trial results are a significant driver of biotech stock prices. The announcement of promising initial efficacy data from the AFFINITY DUCHENNE trial of RGX-202 positions REGENXBIO favorably in the short term, likely leading to increased investor confidence and a rise in stock price.